AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
251.30
+1.95 (+0.78%)
Products, Regulatory

Amgen Says Provides Updated Information On Lumakras Dose Comparison Study

Published: 04/28/2021 07:55 GMT
AMGEN Inc. (AMGN) - Amgen Inc - Agreed Last Night With FDA's Proposed Post-marketing Requirement to Conduct Multi-center Randomized Clinical Trial to Compare Safety and Efficacy of Lumakras™ at 960 Mg Once Daily Versus a Lower Daily Dose of Drug.
Amgen Inc - Anticipates Results From Study in Late 2022.
Amgen Inc - Intends to Proceed With Previously Disclosed Study Comparing 960 Mg Once Daily to a 240 Mg Once Daily Dose.